

was added to a solution of 3D, Ser⁴ 1–12 (0.186 g, 0.096 mmol), in a mixture of 90% acetic acid (8 ml), 1 N hydrochloric acid (0.4 ml), and saturated sodium chloride solution (0.8 ml) at –10°. After stirring for 15 min at –10°, precooled 20% sodium chloride solution (80 ml) was added, and the resulting precipitate was collected and washed with ice-cold water. The still-wet material was dissolved in DMF (20 ml) at –10° and dried over sodium sulfate. The drying agent was filtered off, and a solution of methionylaspartylserylthreonylserylalanylalanine¹⁵ (3E, 13–20; 0.17 g, 0.192 mmol, as monoacetate, trihydrate) in DMF (5 ml) and triethylamine (0.06 ml) was added. The reaction mixture was stirred for 7 days at 5° and for 1 day at room temperature, filtered, and concentrated to 10 ml under reduced pressure and water was added (150 ml). The resultant precipitate was centrifuged, washed with water and ether, and dried, yielding 0.14 g (58%). The crude material (3F, Ser⁴ 1–20) (0.132 g) was dissolved in anhydrous TFA (1.3 ml), and the solution was kept for 150 min at room temperature. An excess of ice-cold ether was added and after 30 min at –10° the peptide was collected by centrifugation, washed with ether, and dried. The residue, dissolved in 0.2 M sodium phosphate buffer (pH 6.4), was purified by passing through an Amberlite CG 50 column, desalted by gel filtration on a Sephadex G-25 column, and lyophilized as described previously. The product (3G, Ser⁴ 1–20) (0.02 g, 19%) had $[\alpha]_D^{25} -70.6 \pm 1^\circ$ (c 0.117, water), single ninhydrin- and Pauly-positive component on paper electrophoresis at pH 1.9, 3.5, 6.4, and 9.5; amino acid ratios in acid hydrolysate: Lys_{2.00}Orn_{1.10}Glu_{2.05}Thr_{2.00}Ala_{3.90}Phe_{0.97}His_{0.97}Met_{0.98}Asp_{0.98}Ser_{3.95}; amino acid ratios in AP-M digest: Lys_{1.97}Orn_{1.01}

Glu_{1.97}Thr_{1.98}Ala_{3.92}Phe_{1.02}His_{0.96}Met_{0.95}Asp_{0.95}(Ser + Gln)_{4.90}. The [Ser⁴,Orn¹⁰]-S-peptide gave, after recombination in 1:1 molar ratio with S-protein, a 40% active partially synthetic ribonuclease.

Lysylglutamylthreonylalanylserylalanyllysylphenylalanylglutamylornithylglutamylhistidylmethionylaspartylserylalanylalanine (3G, Ser⁵ 1–20). The condensation of 3D, Ser⁵ 1–12 (0.315 g, 0.164 mmol), with 3E, 13–20¹⁵ (0.29 g, 0.328 mmol, as monoacetate, trihydrate), by the azide procedure was carried out as described above for 3G, Ser⁴ 1–20, and gave the partially protected [Ser⁵,Orn¹⁰]-S-peptide (3F, Ser⁵ 1–20; 0.357 g, 82%). Treatment of 0.15 g of crude product with anhydrous TFA (1.5 ml), purification on Amberlite CG 50 and on Sephadex G-25, followed by lyophilization gave the pure [Ser⁵,Orn¹⁰]-S-peptide (3G, Ser⁵ 1–20; 0.04 g, 33%); $[\alpha]_D^{25} -71.4 \pm 1^\circ$ (c 0.115, water); single ninhydrin- and Pauly-positive component on paper electrophoresis at pH 1.9, 3.5, 6.4, and 9.5; amino acid ratios in acid hydrolysate: Lys_{2.04}Glu_{2.96}Thr_{1.97}Ala_{4.02}Orn_{1.01}Phe_{1.03}His_{0.99}Met_{0.95}Asp_{0.96}Ser_{3.97}; amino acid ratios in AP-M digest: Lys_{2.03}Glu_{1.99}Thr_{1.95}Ala_{4.02}Orn_{1.03}Phe_{1.02}His_{0.96}Met_{1.02}Asp_{0.98}(Ser + Gln)_{5.00}. The [Ser⁵,Orn¹⁰]-S-peptide gave, after recombination in 1:1 molar ratio with S-protein, a 50% active partially synthetic ribonuclease.

Acknowledgment. The authors wish to thank Dr. E. Celon for carrying out the microanalyses, Dr. L. Carpino for reading the manuscript, and Mr. U. Anselmi and Mr. D. Stivanello for the skillful technical assistance.

Synthesis of Peptide Analogs of the N-Terminal Eicosapeptide Sequence of Ribonuclease A. IX. Synthesis of [Ser⁶,Orn¹⁰]- and [Pro⁶,Orn¹⁰]-eicosapeptides^{1,2}

Fernando Marchiori, Raniero Rocchi, Luigi Moroder, Angelo Fontana, and Ernesto Scoffone

Contribution from Istituto di Chimica Organica dell'Università, Sezione VIII del Centro Nazionale di Chimica delle Macromolecole del CNR, Padua, Italy. Received June 3, 1968

Abstract: Syntheses are described of two analogs of the S-peptide in which the arginyl residue in position 10 is replaced by ornithine and the alanyl residue in position 6 by either serine or proline. The stereochemical homogeneity of these peptides, *i.e.*, lysylglutamylthreonylalanylalanylseryllysylphenylalanylglutamylornithylglutamylhistidylmethionylaspartylserylalanylalanine and lysylglutamylthreonylalanylalanylprolyllysylphenylalanylglutamylornithylglutamylhistidylmethionylaspartylserylalanylalanine, was assessed by digestion with aminopeptidase M followed by quantitative amino acid analysis. The enzymic properties of the two synthetic eicosapeptides were checked, with RNA, after recombination with S-protein. The [Ser⁶,Orn¹⁰]-S-peptide and the [Pro⁶,Orn¹⁰]-S-peptide form respectively a 40 and 15% active partially synthetic ribonuclease at a molar ratio of 1:1 with S-protein.

In a previous communication³ we described the syntheses of [Ser⁴,Orn¹⁰]- and [Ser⁵,Orn¹⁰]-eicosapeptide analogs of the N-terminal sequence of bovine pancreatic ribonuclease A⁴ and we reported that these

(1) The peptides and peptide derivatives mentioned have the L configuration. For a simpler description the customary L designation for individual amino acid residues is omitted. The following abbreviations (IUPAC-IUB Commission on Biochemical Nomenclature, *J. Biol. Chem.*, **241**, 2491 (1966)) are used: Z = benzyloxycarbonyl, Boc = *t*-butoxycarbonyl, OMe = methyl ester, OEt = ethyl ester, OBu^t = *t*-butyl ester, ONp = *p*-nitrophenyl ester, DMF = dimethylformamide, TFA = trifluoroacetic acid.

(2) Some of the results recorded in this paper have been presented at the IXth European Peptide Symposium, Orsay, France, April 15, 1968: E. Scoffone, F. Marchiori, L. Moroder, R. Rocchi, and A. Scaturin, Proceedings of the Symposium, in press.

(3) Part VIII: R. Rocchi, L. Moroder, F. Marchiori, E. Ferrarese, and E. Scoffone, *J. Am. Chem. Soc.*, **90**, 5885 (1968).

synthetic modified S-peptides show high ribonuclease activity after recombination with S-protein in a 1:1 molar ratio when tested with RNA as substrate.


The present study deals with the synthesis of two new eicosapeptide analogs where the arginyl residue in position 10 has been replaced by ornithine and the alanyl residue in position 6 either by serine or proline.

(4) (a) F. M. Richards, *Proc. Natl. Acad. Sci. U.S.A.*, **44**, 162 (1958); RNase A, the principal chromatographic component of beef pancreatic ribonuclease; RNase S, subtilisin-modified RNase A; S-protein, the protein component obtained from RNase S; S-peptide, the eicosapeptide obtained from RNase S; RNase S', the reconstituted enzyme obtained by mixing equimolar amounts of S-peptide and S-protein. (b) According to M. S. Doshier and C. H. W. Hirs, *Federation Proc.*, **25**, 527 (1966), natural S-peptide is a mixture of at least [1–20]-S-peptide and [1–21]-S-peptide.

Chart I. Amino Acid Sequences of S-Peptide and Its Synthetic Analogs

S-Peptide																			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Lys	Glu	Thr	Ala	Ala	Ala	Lys	Phe	Glu	Arg	Gln	His	Met	Asp	Ser	Ser	Thr	Ser	Ala	Ala
[Orn ¹⁰]-S-Peptide																			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Lys	Glu	Thr	Ala	Ala	Ala	Lys	Phe	Glu	Orn	Gln	His	Met	Asp	Ser	Ser	Thr	Ser	Ala	Ala
[Ser ⁶ ,Orn ¹⁰]-S-Peptide																			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Lys	Glu	Thr	Ala	Ala	Ser	Lys	Phe	Glu	Orn	Gln	His	Met	Asp	Ser	Ser	Thr	Ser	Ala	Ala
[Pro ⁶ ,Orn ¹⁰]-S-Peptide																			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Lys	Glu	Thr	Ala	Ala	Pro	Lys	Phe	Glu	Orn	Gln	His	Met	Asp	Ser	Ser	Thr	Ser	Ala	Ala

Chart II. Synthesis of the 1-6 Sequences



The X-ray structure of RNase-S⁵ shows that the section of the S-peptide molecule which contains the sequence 2-12 is in an α -helical conformation and that the alanyl residue in position 4 appears to be involved in the hydrophobic interaction responsible for the correct S-peptide-S-protein association. The results of our substitution at positions 4 and 5 showed that direct hydrophobic interactions between the alanyl-4 or -5 side-chain residue and groups in the protein appears to be of little significance.

In order to see how the alanyl residue in position 6 affects the ability of the S-peptide to assume its correct conformation when it is bound to S-protein, we synthesized the [Ser⁶,Orn¹⁰]-S-peptide (Chart I).

The findings of Beintema,⁶ that an aspartyl residue replaces alanine-6 in the rat ribonuclease sequence, makes probable that the substitution of the apolar residue in position 6 by an amino acid with a polar side chain does not significantly affect the catalytic function.

In order to explore the influence of the dimensions of the helical portion on the S-peptide's ability to bind and to activate the S-protein, we carried out the synthesis of the [Pro⁶,Orn¹⁰]-S-peptide (Chart I). The steric restrictions of proline prevent such a residue from taking part in an α -helical conformation. The expected consequence of the replacement of alanine-6 with pro-

line is then a shortening or the disappearance of the helical section of the S-peptide, which could affect its capacity to regenerate ribonuclease activity with the S-protein.

The activity data show that both synthetic analogs are able to catalyze the depolymerization of RNA, after recombination with S-protein in a 1:1 molar ratio. The [Ser⁶,Orn¹⁰]- and the [Pro⁶,Orn¹⁰]-RNase S' show about 65 and 25%, respectively, of the enzymic activity of [Orn¹⁰]-RNase S' ⁷ (40 and 15% in comparison with RNase S').

Since the alanyl residues in positions 4, 5, or 6 can be replaced by the seryl residue without significantly affecting the potential catalytic properties of the resulting S-peptide analogs, it is possible to conclude that the hydrophobic character of these residues is not an important feature for the correct peptide-protein association.


Moreover, the potential catalytic activity of the synthetic analog containing, in position 6, an imino acid (proline) in place of an amino acid (alanine) shows that such a modified eicosapeptide still possesses those basic structural features which are responsible for the activation of the S-protein in spite of the considerable difference in conformation which undoubtedly is found in the polypeptide backbone.

(5) H. W. Wyckoff, K. D. Hardman, N. M. Allewell, T. Inagami, L. N. Johnson, and F. M. Richards, *J. Biol. Chem.*, **242**, 3984 (1967).

(6) J. J. Beintema and M. G. Gruber, *Biochim. Biophys. Acta*, **147**, 612 (1967).

(7) (a) E. Scoffone, F. Marchiori, R. Rocchi, G. Vidali, A. M. Tamburro, A. Scatturin, and A. Marzotto, *Tetrahedron Letters*, 943 (1966); (b) E. Scoffone, R. Rocchi, F. Marchiori, A. Marzotto, A. Scatturin, A. M. Tamburro, and G. Vidali, *J. Chem. Soc., C*, 606 (1967).

Chart III. Synthesis of the 1-20 Sequences



These findings agree with Hofmann's⁸ observation that the heptapeptide N⁶-formylsphenylalanylglutamylarginylglutamylhistidylmethionine still possesses the ability to activate the S-protein, with RNA as substrate (although at high peptide:protein molar ratios).

We demonstrated⁹ that the S-peptide is essentially randomly coiled in the absence of the partner S-protein while it undergoes a coil-to-helix transition in the presence of the protein.

If one assumes that the existence of a helical portion in the S-peptide, stabilized by a cooperative effect of S-protein, is essential to facilitate the hydrophobic interactions which allow the association process, it is possible to deduce, from the above-mentioned findings, that only the helical section including residue 7-12 is essential for the correct peptide-protein binding, while residue 2-6 could be in a different conformation without a remarkable effect on the affinity of synthetic peptides for S-protein. A more detailed examination of the enzymic properties of [Ser⁶,Orn¹⁰]- and [Pro⁶,Orn¹⁰]-S-peptide including the evaluation of their conformational stability will be reported in a forthcoming paper.

Peptide Syntheses

The synthetic route to [Ser⁶,Orn¹⁰]- and [Pro⁶,Orn¹⁰]-S-peptide, illustrated in Charts II and III, is similar to that which was used for the preparation of other analogs.^{3,7,10} The sequence 1-6 was prepared by condensing the azide corresponding to the N^α,N^ε-di-*t*-butyloxycarbonyllseryl-γ-*t*-butylglutamylthreonine hy-

drazide¹¹ (2D, 1-3) with alanylalanylserine methyl ester (2E, Ser⁶ 4-6) or alanylalanylproline methyl ester (2E, Pro⁶ 4-6), respectively, to give the two protected hexapeptides 2F, Ser⁶ or 2F, Pro⁶ 1-6.

The above-mentioned hexapeptides were converted into hydrazides (2G or 3A, Ser⁶ 1-6, and 2G or 3A, Pro⁶ 1-6) in the usual manner.

The corresponding azides (3B, Ser⁶ or Pro⁶ 1-6) were coupled with N⁶-*t*-butyloxycarbonyllsphenylalanyl-γ-*t*-butylglutamyl-N⁸-*t*-butyloxycarbonylornithylglutamylhistidine methyl ester (3B, 7-12) obtained by catalytic hydrogenolysis from the corresponding N^α-benzyloxycarbonyl derivative¹² (3A, 7-12) to give the two protected dodecapeptides esters (3C, Ser⁶ or Pro⁶ 1-12).

The esters were converted into hydrazides (3D, Ser⁶ or Pro⁶ 1-12) and azides (3E, Ser⁶ or Pro⁶ 1-12) which were coupled with the octapeptide methionylaspartylserylserylthreonylserylalanylalanine¹³ (3E, 13-20) to give the partially protected eicosapeptides 3F, Ser⁶ or Pro⁶ 1-20. The protecting groups were removed by exposure to TFA, and the crude eicosapeptides 3G, Ser⁶ or Pro⁶ 1-20, were purified by chromatography through an Amberlite CG 50 column eluted with 0.2 M sodium phosphate, desalted by gel filtration on Sephadex G-25 using 5% acetic acid as the eluent, and lyophilized. The chemical homogeneity of both S-peptide analogs was evaluated by electrophoresis at different pH values and quantitative amino acid analysis of the acid hydrolysates. Aminopeptidase M (AP-M) was employed for the evaluation of the stereochemical homogeneity of synthetic materials according to the procedure suggested by Hofmann.¹⁴

(8) F. M. Finn and K. Hofmann, *J. Am. Chem. Soc.*, **87**, 645 (1965).

(9) A. Scatturin, A. M. Tamburro, R. Rocchi, and E. Scoffone, *Chem. Commun.*, 1273 (1967).

(10) (a) R. Rocchi, F. Marchiori, L. Moroder, A. Fontana, and E. Scoffone, *Gazz. Chim. Ital.*, **96**, 1537 (1966); (b) F. Marchiori, R. Rocchi, L. Moroder, and E. Scoffone, *ibid.*, **96**, 1549 (1966); (c) E. Scoffone, R. Rocchi, F. Marchiori, L. Moroder, A. Marzotto, and A. M. Tamburro, *J. Am. Chem. Soc.*, **89**, 5450 (1967).

(11) E. Scoffone, R. Rocchi, G. Vidali, A. Scatturin, and F. Marchiori, *Gazz. Chim. Ital.*, **94**, 743 (1964).

(12) F. Marchiori, R. Rocchi, G. Vidali, A. M. Tamburro, and E. Scoffone, *J. Chem. Soc., C*, 81 (1967).

(13) F. Marchiori, R. Rocchi, L. Moroder, G. Vidali, and E. Scoffone, *ibid.*, 89 (1967).

(14) K. Hofmann, F. M. Finn, M. Limetti, J. Montibeller, and G. Zanetti, *J. Am. Chem. Soc.*, **88**, 3633 (1966).

Experimental Section¹⁵

RNase A was prepared by the procedure of Crestfield, *et al.*,¹⁶ starting with bovine pancreatic ribonuclease (Fluka AG four times crystallized). RNase S, S-protein, and S-peptide were prepared from RNase A, essentially by the method of Richards.^{15,17}

Aminopeptidase M (AP-M) was obtained from Rohm and Haas HmbH, Darmstadt, West Germany. Yeast RNA, obtained from Schwarz Laboratories, was purified according to the procedure of Wellner, *et al.*¹⁸

The crude S-peptide analogs (100–200 mg) obtained by treatment of the partially protected eicosapeptide with TFA were dissolved in 0.2 M sodium phosphate buffer (pH 6.47) and purified by passing the solutions through an Amberlite CG 50 column (1.8 × 90 cm) with the same phosphate buffer as the eluent. Individual fractions (2.5 ml) were collected (rate *ca.* 16 ml/hr) and the products detected by the ninhydrin test and the Pauly reaction.

The ninhydrin- and Pauly-positive fractions were pooled, concentrated under reduced pressure, lyophilized, and desalted by passing through a Sephadex G-25 column (1.8 × 140 cm) with 5% acetic acid as the eluent. The peptide was detected as described above, and the peptide-containing fractions were pooled, concentrated to a syrup, and lyophilized from water to constant weight.

Benzylloxycarbonylalanylserine Methyl Ester (2B, Ser⁶ 5–6). Benzylloxycarbonylalanine *p*-nitrophenyl ester¹⁹ (20.66 g, 60.0 mmol) and triethylamine (8.4 ml) were added to a pyridine solution (150 ml) containing the serine methyl ester²⁰ (prepared from 10.23 g, 66.0 mmol, of the hydrochloride with 2 N ammonia in chloroform in the usual manner), and the reaction mixture was kept overnight at room temperature. The solvent was then removed *in vacuo* and the residue crystallized twice from ethyl acetate and once from ethanol–petroleum ether (bp 30–60°); yield 15.18 g (78%); mp 134–135° (lit.²¹ mp 134–135°); $[\alpha]^{20}_D -20.5 \pm 0.2^\circ$ (*c* 1.0, methanol). Alternatively in another experiment the residue obtained by removing the solvent from the reaction mixture was taken up in ethyl acetate and washed successively with 5% sodium carbonate, 1 N hydrochloric acid, and water. The solution was then dried over sodium sulfate and evaporated to dryness. Crystallization of the residue from ethanol–petroleum ether gave only 44% yield of the pure product, probably owing to its partial solubility in water.

Benzylloxycarbonylalanylproline Methyl Ester (2B, Pro⁶ 5–6). Benzylloxycarbonylalanine *p*-nitrophenyl ester¹⁹ (5.86 g, 17 mmol) and triethylamine (5.2 ml) were added to a pyridine solution (100 ml) containing proline methyl ester hydrochloride²² (3.31 g, 20 mmol), and the reaction mixture was kept 20 hr at room temperature. The solvent was then removed *in vacuo*, and the residue, taken up in ethyl acetate, was thoroughly washed with 5% sodium carbonate, 1 N hydrochloric acid, and water. The solution, dried over sodium sulfate and taken to dryness *in vacuo*, gave the title compound as an oil; yield 4.34 g (76%); R_f 0.73, R_f 0.95; single ninhydrin-negative and chlorine-positive spot.

Since our attempts to crystallize the oily methyl ester failed, the characterization of 2B, Pro⁶ 5–6, was achieved as follows. Benzylloxycarbonylalanylproline methyl ester (0.2 g, 0.6 mmol) was dissolved in acetone (2 ml); 1 N sodium hydroxide (0.66 ml) was added, and the solution was stirred for 45 min at room temperature. The acetone was then removed under reduced pressure. The residue was dissolved in water (30 ml), and the solution was extracted twice with ether (two 30-ml portions), cooled to 2°, and acidified to pH 2 with 1 N hydrochloric acid. The acid solution was extracted three times with ethyl acetate (three 30-ml portions), and the combined organic layers were thoroughly washed with water,

dried over sodium sulfate, and concentrated to small volume *in vacuo*. Dicyclohexylamine (0.14 ml) was added, and the resulting dicyclohexylammonium salt was precipitated by addition of ether, collected, and dried *in vacuo* over concentrated sulfuric acid; yield 0.225 g (71%); mp 204–205°; $[\alpha]^{20}_D -58.4 \pm 0.2^\circ$ (*c* 1.0, glacial acetic acid).

Anal. Calcd for C₂₈H₄₃N₃O₅ (501.66): C, 67.0; H, 8.7; N, 8.4. Found: C, 67.2; H, 8.6; N, 8.5.

Benzylloxycarbonylalanylserine Methyl Ester (2D, Ser⁶ 4–6). Benzylloxycarbonylalanine *p*-nitrophenyl ester¹⁹ (14.63 g, 42.5 mmol) and triethylamine (12 ml) were added to a pyridine solution (300 ml) of alanylserine methyl ester acetate obtained by hydrogenolysis of 2B, Ser⁶ 5–6 (14.9 g, 46.0 mmol), in 50% methanolic acetic acid (300 ml). The reaction mixture was kept 24 hr at room temperature, the solvent was evaporated to dryness *in vacuo*, and the residue was crystallized twice from ethyl acetate and once from ethanol–ether; yield 11.6 g (69%); mp 192–193°; $[\alpha]^{20}_D -52.0 \pm 0.5^\circ$ (*c* 1.0, methanol); R_f 0.70, R_f 0.85; single ninhydrin-negative and chlorine-positive spot.

Anal. Calcd for C₁₈H₂₅N₃O₇ (395.4): C, 54.7; H, 6.4; N, 10.6. Found: C, 54.6; H, 6.2; N, 10.6.

As in the case of 2B, Ser⁶ 5–6, the yield of pure product dropped to 22% when the purification of the residue, obtained by evaporation of the solvent from the reaction mixture, was carried out by taking up this residue in ethyl acetate and washing with 5% sodium carbonate, 1 N hydrochloric acid, and water.

Benzylloxycarbonylalanylproline Methyl Ester (2D, Pro⁶ 4–6). Benzylloxycarbonylalanylproline methyl ester (2B, Pro⁶ 5–6) (4.14 g, 12.37 mmol) was dissolved in 2.5 N hydrobromic acid in glacial acetic acid and kept at 50° for 45 min and at room temperature for an additional hour. Ether was added to precipitate the dipeptide hydrobromide, and the oily residue was collected, dissolved in methanol, and reprecipitated with ether (three times). The resulting oil (2.78 g, 80%) was dried *in vacuo* over potassium hydroxide pellets and proved to be chromatographically homogeneous; R_f 0.35, R_f 0.30. The alanylproline methyl ester hydrobromide was dissolved in pyridine, and benzylloxycarbonylalanine *p*-nitrophenyl ester¹⁹ (3.1 g, 9 mmol) and triethylamine (2.65 ml) were added. The reaction mixture was kept 40 hr at room temperature, then the solvent was evaporated to dryness *in vacuo*, and the residue, taken up in ethyl acetate, was washed with 5% sodium carbonate, 1 N hydrochloric acid, and water and dried over sodium sulfate. The solvent was removed under reduced pressure, and the product was crystallized twice from methanol–ether; yield 1.6 g (44%); mp 130–131°; $[\alpha]^{20}_D -116.9 \pm 0.5^\circ$ (*c* 1.0, glacial acetic acid); R_f 0.70, R_f 0.95; single ninhydrin-negative and chlorine-positive spot.

Anal. Calcd for C₂₀H₂₇N₃O₈ (405.44): C, 59.2; H, 6.7; N, 10.4. Found: C, 59.1; H, 6.7; N, 10.4.

N^α,N^ε-Di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonylalanylserine Methyl Ester (2F, Ser⁶ 1–6). Sodium nitrite (1 M, 4.2 ml) was added to a solution of N^α,N^ε-di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonine hydrazide¹¹ (2D, 1–3; 2.59 g, 4.0 mmol) in a mixture of glacial acetic acid (20 ml), 1 N hydrochloric acid (8 ml), and saturated sodium chloride (4 ml) cooled to –10°. After stirring at –10° for 15 min precooled saturated sodium chloride (15 ml) and ice-cold water (15 ml) were added, and the N^α,N^ε-di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonine azide (2E, 1–3) was extracted with three 20-ml portions of ethyl acetate cooled to –10°. The combined organic layers were quickly washed with ice-cold, saturated solutions of potassium carbonate and sodium chloride and dried, for 10 min, at –10° over sodium sulfate. Simultaneously, benzylloxycarbonylalanylserine methyl ester (2D, Ser⁶ 4–6) (1.78 g, 4.5 mmol) was dissolved in methanol (100 ml) and hydrogenated for 4 hr and the catalyst filtered off. The filtrate was evaporated to dryness under reduced pressure, and the residue was dissolved in methanol. Precipitation occurred on addition of ether. The product was dissolved in DMF (25 ml) containing triethylamine (1.1 ml) and added to the ethyl acetate solution of the protected tripeptide azide (2E, 1–3) prepared above. The resulting solution was concentrated under reduced pressure, at 0°, to remove most of the ethyl acetate and then allowed to react at 5° for 5 days whereupon ether was added. The precipitate was collected, washed with ether, and crystallized twice from DMF–ethyl acetate; yield 2.80 g (80%); mp 182–184°; $[\alpha]^{20}_D -15.3 \pm 0.5^\circ$ (*c* 1.0, DMF); R_f 0.80, R_f 0.90; single ninhydrin-negative and chlorine-positive spot.

Anal. Calcd for C₃₅H₆₀N₇O₁₅ (876.0): C, 53.5; H, 8.0; N, 11.2. Found: C, 53.2; H, 7.9; N, 11.4.

(15) General experimental and analytical procedures used were those described in paper VIII of this series.³

(16) A. M. Crestfield, W. H. Stein, and S. Moore, *J. Biol. Chem.*, **238**, 618 (1963).

(17) (a) F. M. Richards and P. J. Vithayathil, *ibid.*, **234**, 1459 (1959); (b) G. Gordillo, P. J. Vithayathil, and F. M. Richards, *Yale J. Biol. Med.*, **34**, 582 (1962); (c) A. Marzotto, A. Scatturin, G. Vidali, and E. Scoffone, *Gazz. Chim. Ital.*, **94**, 760 (1964).

(18) D. Wellner, H. J. Silman, and M. Sela, *J. Biol. Chem.*, **238**, 1324 (1963).

(19) F. Marchiori, R. Rocchi, and E. Scoffone, *Ric. Sci. Rend.*, **A2**, 647 (1962).

(20) St. Guttmann and R. A. Boissonnas, *Helv. Chim. Acta*, **41**, 1852 (1958).

(21) J. A. McLaren, W. E. Savige, and J. M. Swan, *Australian J. Chem.*, **11**, 345 (1958).

(22) St. Guttmann, *Helv. Chim. Acta*, **44**, 721 (1961).

N^α,N^ε-Di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonylalanylalanylproline Methyl Ester (2F, Pro⁶ 1–6). The condensation of 2E, 1–3 (obtained from 2.52 g, 3.9 mmol of 2D, 1–3¹¹), with 2E, Pro⁶ 4–6 (*R*_f 0.30; obtained by hydrogenolysis in methanol from 1.58 g, 3.9 mmol, of 2D, Pro⁶ 4–6), was carried out by the same procedure described above for 2F, Ser⁶ 1–6. After 6 days at 5°, the solvent was removed *in vacuo* from the reaction mixture, and the residue, taken up in chloroform, was extracted with 5% sodium carbonate, 5% citric acid, and water. The solution was dried over sodium sulfate and evaporated to dryness *in vacuo*. The residue was crystallized from methanol–ethyl acetate and recrystallized from methanol–ether; yield 2.62 g (76%); mp 140–141°; [α]_D²⁰ –41 ± 0.5° (*c* 1.0, DMF); *R*_f 0.70, *R*₂ 0.80; single ninhydrin-negative and chlorine-positive spot.

Anal. Calcd for C₄₁H₇₁N₉O₁₄ (886.09): C, 55.5; H, 8.1; N, 11.1. Found: C, 54.8; H, 8.1; N, 10.9.

N^α,N^ε-Di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonylalanylalanyls erine Hydrazide (2G, Ser⁶ 1–6, or 3A, Ser⁶ 1–6). The protected hexapeptide methyl ester 2F, Ser⁶ 1–6 (2.63 g, 3.0 mmol), was dissolved in DMF (70 ml), and hydrazine hydrate (2.5 ml) was added. The reaction mixture was kept overnight at 60° and then at room temperature for 4 days. The slightly turbid solution was filtered and concentrated under reduced pressure, and the product was precipitated by addition of ethanol. The precipitate was collected by centrifugation, washed with ethanol and ether, recrystallized twice from DMF–ether, and dried *in vacuo* over concentrated sulfuric acid; yield 2.26 g (86%); mp 217–218°; [α]_D²² –34.0 ± 0.5° (*c* 1.0, glacial acetic acid); *R*_f 0.65, *R*₂ 0.95; single chlorine- and picryl chloride positive spot.

Anal. Calcd for C₃₈H₆₉N₉O₁₄ (876.0): C, 52.1; H, 7.9; N, 14.4. Found: C, 52.0; H, 8.0; N, 14.5.

N^α,N^ε-Di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonylalanylalanylproline hydrazide (2G, Pro⁶ 1–6, or 3A, Pro⁶ 1–6) was obtained by addition of hydrazine hydrate (2.5 ml) to a solution of 2F, Pro⁶ 1–6 (2.5 g, 2.82 mmol), in DMF (50 ml). After heating for 1 hr at 70° the reaction mixture was kept 3 days at room temperature. The solution was concentrated under reduced pressure, and the product was precipitated by addition of water. The precipitate was collected, washed with water, dried *in vacuo* over concentrated sulfuric acid, and crystallized twice from DMF–ether, yielding 1.44 g (57%); mp 144–145°; [α]_D²⁰ –69.6 ± 0.2° (*c* 1.0, 90% acetic acid); *R*_f 0.55, *R*₂ 0.80; single chlorine- and picryl chloride positive spot.

Anal. Calcd for C₄₀H₇₁N₉O₁₃ (886.1): C, 54.2; H, 8.1; N, 14.2. Found: C, 53.7; H, 7.8; N, 14.1.

N^ε-*t*-Butyloxycarbonyllysylphenylalanyl-γ-*t*-butylglutamyl-N^δ-*t*-butyloxycarbonylornithylglutamylhistidine Methyl Ester Acetate (3B, 7–12). We have previously reported^{3,10} the hydrogenolysis of 3A, 7–12, to prepare some dodecapeptide analogs corresponding to the 1–12 sequence of the S-peptide. We have now isolated and characterized the N^α-free hexapeptide 3B, 7–12, as the acetate salt. The N^α-benzyloxycarbonyl group was removed from 3A, 7–12, by hydrogenating for 2 hr over 10% palladized charcoal, the protected hexapeptide (1.325 g, 1.1 mmol) dissolved in a mixture of glacial acetic acid (60 ml) and methanol (20 ml). The catalyst was filtered off, the solvent evaporated under reduced pressure, and the residue crystallized twice from methanol–ether; yield 0.97 g (78%); mp 173–175°; [α]_D²⁰ –12.0 ± 0.2° (*c* 1.0, DMF); *R*_f 0.55, *R*₂ 0.20; single ninhydrin-, chlorine-, and Pauly-positive spot.

Anal. Calcd for C₃₃H₅₃N₁₁O₁₈ (1132.36): C, 56.2; H, 7.5; N, 13.6. Found: C, 56.1; H, 7.6; N, 13.8.

N^α,N^ε-Di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonylalanylalanylseryl-N^ε-*t*-butyloxycarbonyllysylphenylalanyl-γ-*t*-butylglutamyl-N^δ-*t*-butyloxycarbonylornithylglutamylhistidine Methyl Ester (3C, Ser⁶ 1–12). Sodium nitrite (1 *M*, 0.6 ml) was added to a solution of 3A, Ser⁶ 1–6 (0.442 g, 0.504 mmol), in a mixture of glacial acetic acid (6 ml), 1 *N* hydrochloric acid (1.2 ml), and 20% sodium chloride (2 ml) at –10°. After stirring for 20 min at –10°, precooled 20% sodium chloride (60 ml) was added, and the resulting precipitate was collected by centrifugation and washed with ice-cold water. The moist azide was then dissolved in DMF (50 ml) at –10°, dried over sodium sulfate, and added to a solution of N^ε-*t*-butyloxycarbonyllysylphenylalanyl-γ-*t*-butylglutamyl-N^δ-*t*-butyloxycarbonylornithylglutamylhistidine methyl ester acetate (3B, 7–12) (0.57 g, 0.504 mmol) in DMF (20 ml) containing triethylamine (0.15 ml). The reaction mixture was kept 6 days at 5° and a further 24 hr at room temperature, the solution was concentrated under reduced pressure, and precipitation occurred on addition of water. The precipitate was collected by centrifuga-

tion, washed with water, and dried *in vacuo* over phosphorus pentoxide. Crystallization of the crude material from DMF–ether gave the pure product; yield 0.242 g (25%); mp 232–233°; [α]_D²⁰ –19.6 ± 0.5° (*c* 1.0, DMF); *R*_f 0.85, *R*₂ 0.95; single ninhydrin-negative and chlorine- and Pauly-positive spot; amino acid ratios in acid hydrolysate: Lys_{1.97}Orn_{1.05}Glu_{3.00}Thr_{0.95}Ser_{0.95}Ala_{2.00}Phe_{0.95}His_{0.95}.

Anal. Calcd for C₅₉H₁₄₈N₁₈O₂₈ (1916.3): C, 55.8; H, 7.7; N, 13.2. Found: C, 55.6; H, 7.6; N, 13.0.

N^α,N^ε-Di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonylalanylalanylseryl-N^ε-*t*-butyloxycarbonyllysylphenylalanyl-γ-*t*-butylglutamyl-N^δ-*t*-butyloxycarbonylornithylglutamylhistidine methyl ester (3C, Pro⁶ 1–12) was prepared by condensation of 3B, Pro⁶ 1–6 (obtained from 0.532 g, 0.6 mmol, of 3A, Pro⁶ 1–6), with 3B, 7–12 (0.68 g, 0.6 mmol), by an azide coupling step as described above for the preparation of 3C, Ser⁶ 1–12; yield 0.8 g (69%); mp 184–185°; [α]_D²⁰ –27.5 ± 0.5° (*c* 1.0, DMF); *R*_f 0.80, *R*₂ 0.95; single ninhydrin-negative and chlorine- and Pauly-positive spot; amino acid ratios in acid hydrolysate: Lys_{1.90}Orn_{1.10}His_{0.95}Glu_{3.16}Thr_{0.92}Ala_{1.90}Pro_{0.95}.

Anal. Calcd for C₉₁H₁₄₈O₂₇N₁₈ (1926.35): C, 56.7; H, 7.8; N, 13.1. Found: C, 56.0; H, 7.8; N, 12.8.

N^α,N^ε-Di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonylalanylalanylseryl-N^ε-*t*-butyloxycarbonyllysylphenylalanyl-γ-*t*-butylglutamyl-N^δ-*t*-butyloxycarbonylornithylglutamylhistidine Hydrazide (3D, Ser⁶ 1–12). The dodecapeptide methyl ester 3C, Ser⁶ 1–12 (0.230 g, 0.12 mmol), was dissolved in DMF (10 ml), and hydrazine hydrate (0.28 ml) was added. The solution was heated for 1 hr at 70°, the hydrazine hydrate (0.14 ml) was then added, and the reaction mixture was kept overnight at 50° and then a further 3 days at room temperature. The solution was concentrated under reduced pressure, ether was added, and the precipitate was collected, washed with ether, and dried *in vacuo* over concentrated sulfuric acid. The crude product was recrystallized from DMF–water; yield 0.198 g (86%); mp 240–242° dec; [α]_D²⁰ –25.5 ± 0.5° (*c* 1.0, 90% acetic acid); *R*_f 0.70, *R*₂ 0.95; single Pauly-, chlorine-, and picryl chloride positive spot.

Anal. Calcd for C₈₈H₁₄₆N₂₀O₂₇ (1916.3): C, 55.1; H, 7.7; N, 14.6. Found: C, 54.8; H, 7.6; N, 14.5.

N^α,N^ε-Di-*t*-butyloxycarbonyllysyl-γ-*t*-butylglutamylthreonylalanylalanylprolyl-N^ε-*t*-butyloxycarbonyllysylphenylalanyl-γ-*t*-butylglutamyl-N^δ-*t*-butyloxycarbonylornithylglutamylhistidine hydrazide (3D, Pro⁶ 1–12) was prepared from the corresponding methyl ester (3C, Pro⁶ 1–12; 0.79 g, 0.41 mmol) by the procedure described above for 3D, Ser⁶ 1–12. The product (0.557 g, 70%) had mp 203–205°; [α]_D²⁰ –43.4 ± 0.5° (*c* 0.96, 90% acetic acid); *R*_f 0.75, *R*₂ 0.90; single Pauly-, chlorine-, and picryl chloride positive spot.

Anal. Calcd for C₉₀H₁₄₈O₂₈N₂₀ (1926.36): C, 56.1; H, 7.7; N, 14.5. Found: C, 55.6; H, 7.7; N, 14.2.

Lysylglutamylthreonylalanylalanylseryllysylphenylalanylglutamylornithylglutamylhistidylmethionylaspartylserylserylthreonylserylalanylalanine (3G, Ser⁶ 1–20). Sodium nitrite (1 *M*, 0.3 ml) was added to a solution of 3D, Ser⁶ 1–12 (0.198 g, 0.103 mmol), in a mixture of 90% acetic acid (10 ml), 1 *N* hydrochloric acid (0.6 ml), and saturated sodium chloride (0.8 ml) at –10°. After stirring for 15 min at –10°, precooled 20% sodium chloride (80 ml) was added, and the resulting precipitate was collected and washed with ice-cold water. The still wet material was dissolved in DMF (20 ml) at –10° and dried over sodium sulfate. The drying agent was filtered off, and a solution of methionylaspartylserylserylthreonylserylalanylalanine¹³ (3E, 13–20; 0.182 g, 0.206 mmol, as monoacetate trihydrate) in DMF (5 ml) and triethylamine (0.06 ml) was added. The reaction mixture was stirred for 7 days at 5° and for 1 day at room temperature, filtered, and concentrated to 10 ml under reduced pressure, and water was added (150 ml). The resultant precipitate was centrifuged, washed with water and ether, and dried, yielding 0.153 g (58%). The crude material (3F, Ser⁶ 1–20) was dissolved in anhydrous TFA (1.5 ml), and the solution was kept for 150 min at room temperature. An excess of ice-cold ether was added, and after 30 min at –10° the peptide was collected by centrifugation, washed with ether, and dried. The residue, dissolved in 0.2 *M* sodium phosphate buffer (pH 6.4), was purified by passing through an Amberlite CG 50 column, desalted by gel filtration on a Sephadex G-25 column, and lyophilized as described previously. The product (3G, Ser⁶ 1–20) (0.03 g, 24.4%) had [α]_D²² –65.1 ± 2° (*c* 0.11, water) and a single ninhydrin- and Pauly-positive component on paper electrophoresis at pH 1.9, 3.5, 6.4, and 9.5; amino acid ratios in acid hydrolysate: Lys_{1.99}Orn_{1.05}Glu_{2.90}Thr_{2.00}Ala_{3.90}Phe_{0.97}His_{0.96}Met_{0.97}Asp_{0.98}Ser_{3.95}; amino acid ratios in AP-M di-

gest: Lys_{2.05}Orn_{1.05}Glu_{1.99}Thr_{1.90}Ala_{4.05}Phe_{1.00}His_{0.95}Met_{1.02}Asp_{0.96}(Ser + Gln)_{4.90}. The [Ser⁶,Orn¹⁰]-S-peptide gave, after recombination in a 1:1 molar ratio with S-protein, a 40% active partially synthetic ribonuclease.

Lysylglutamylthreonylalanylalanylprolyllysylphenylalanylglutamylornithylglutamylhistidylmethionylaspartylserylserylthreonylserylalanylalanine (3G, Pro⁶ 1-20). The condensation of 3D, Pro⁶ 1-12 (0.335 g, 0.174 mmol), with 3E, 13-20¹³ (0.306 g, 0.348 mmol, as monoacetate, trihydrate), by the azide procedure was carried out as described above for 3G, Ser⁶ 1-20, and gave the partially protected [Pro⁶,Orn¹⁰]-S-peptide (3F, Ser⁶ 1-20; 0.264 g, 57%). Treatment of the crude product with anhydrous TFA (2.5 ml), purification on Amberlite CG 50 and on Sephadex G-25, followed by lyophilization gave the pure [Pro⁶,Orn¹¹]-S-peptide (3G, Pro⁶ 1-20; 0.053 g, 25%), [α]_D²⁰ -97.5 \pm 1° (c 0.117, water);

single ninhydrin- and Pauly-positive component on paper electrophoresis at pH 1.9, 3.5, 6.4, and 9.5; amino acid ratios in acid hydrolysate: Lys_{2.00}Glu_{2.96}Thr_{1.95}Ala_{3.80}Orn_{1.00}Phe_{1.05}His_{1.05}Pro_{0.95}Met_{0.97}Asp_{1.06}Ser_{2.95}; amino acid ratios in AP-M digest: Lys_{1.97}Glu_{1.95}Thr_{2.00}Ala_{3.80}Orn_{0.95}Phe_{0.97}His_{0.97}Pro_{0.97}Met_{1.00}Asp_{0.95}(Ser + Gln)_{4.05}. The [Pro⁶,Orn¹⁰]-S-peptide gave, after recombination in a 1:1 molar ratio with S-protein, a 15% active partially synthetic ribonuclease.


Acknowledgment. The authors wish to thank Dr. E. Celon for carrying out the microanalyses, Professor J. Steigman for reading the manuscript, and Mr. U. Anselmi and Mr. D. Stivanello for their skillful technical assistance.

Communications to the Editor

Isolation and Characterization of a New Prostaglandin Isomer

Sir:

Prostaglandins are biosynthesized from C-20 polyunsaturated fatty acids when the latter are incubated in a variety of mammalian tissue homogenates;¹ for example, prostaglandin E₁ (PGE₁) (1) has been obtained from all-*cis*-8,11,14-eicosatrienoic acid. In addition to PGE₁, the corresponding 9 α -hydroxy compound, prostaglandin F₁ α (PGF₁ α), has also been obtained from the same C-20:3 acid,² and recently an isomer of PGE₁, 11-dehydro-PGF₁ α , has been isolated as the main product when a purified microsomal enzyme fraction from sheep seminal vesicular glands was employed for the conversion.³ We wish to report the isolation and structure determination of a new isomer of PGE₁, namely 8-isoprostaglandin E₁ (2). This acid is of special interest in view of its chemical instability and significant biological properties. Relative to PGE₁ this new isomer has only very low activity in stimulating smooth muscle contraction *in vitro* or in



causing an acute vasodepression in rats,⁴ but is of the same order of potency as PGE₁ in its antilipolytic effects and in its inhibition of platelet aggregation.⁴ Conditions for the large-scale bioconversion of all-*cis*-

8,11,14-eicosatrienoic acid and extraction and purification of PGE₁ have been described earlier.⁵ Mother liquors (20.9 g) from the crystallization of PGE₁ obtained biosynthetically were chromatographed on an Amberlyst-15 (silver form) ion-exchange column.⁵ The fraction (11.0 g) containing both PGE₁ and 8-iso-PGE₁ was further fractionated on a column containing acid-washed silica gel (E. Merck AG., 0.05-2 mm). Solvents containing an increasing concentration of ethyl acetate in benzene were used for elution. Crystallization of a fraction eluted just prior to PGE₁ from an ethyl acetate-hexane mixture yielded 955 mg of material⁶ which had a slightly faster mobility than PGE₁ on silica gel thin layers using system A IX⁷ for development. The infrared spectrum (Nujol) of 8-iso-PGE₁ showed evidence for the presence of the same functional groups as in PGE₁⁸ but was clearly different from the spectrum of PGE₁ in the fingerprint region. The mass spectra of the 8-iso-PGE₁ and its methyl ester were identical with the corresponding spectra of PGE₁ and PGE₁ methyl ester.⁸ When 8-iso-PGE₁ was treated at 37° for 1 hr with 1 N sodium hydroxide a material was obtained that was identical with prostaglandin B₁ by thin layer chromatography and mass spectrometry (as the methyl ester) and in the sign and shape of its optical rotatory dispersion curve between 310 and 600 m μ .

The ORD spectrum of 8-iso-PGE₁ is nearly the mirror image of that of PGE₁ which has a negative Cotton effect curve.⁸ As the most important determinant of the sign of the Cotton effect in cyclopentanones seems to be the stereochemistry of substituents α to the ketone, this suggests that a change has occurred at the C-8 position to give a β -oriented carboxy side chain (*i.e.*,

(1) D. A. van Dorp, R. K. Beerthuis, D. H. Nugteren, and H. Vonkeman, *Biochim. Biophys. Acta*, **90**, 204 (1964); S. Bergstrom, H. Danielsson, and B. Samuelsson, *ibid.*, **90**, 207 (1964); S. Bergstrom, L. A. Carlson, and J. R. Weeks, *Pharmacol. Rev.*, **20**, 1 (1968).

(2) F. P. Kupiecki, *Life Sci.*, **4**, 1811 (1965).

(3) W. E. Lands, E. Granstrom, and B. Samuelsson, *J. Biol. Chem.*, in press.

(4) J. R. Weeks, N. C. Sekhar, and F. P. Kupiecki, *Pharmacologist*, in press. For recent reviews of the biological activity of the prostaglandins, see S. Bergstrom, *Science*, **157**, 382 (1967); S. Bergstrom, L. A. Carlson, and J. R. Weeks, *Pharmacol. Rev.*, **20**, 1 (1968).

(5) E. G. Daniels and J. E. Pike, Abstracts, Symposium on Prostaglandins, Worcester Foundation, 1967, to be published.

(6) Material which was pure by other criteria sometimes exhibited a melting point range of about 70-88°. Slow heating on a Kofler microscope hot stage showed the presence of several crystal polymorphs melting and resolidifying over this range. Some samples from ethyl acetate-Skellysolve B melted cleanly at 87-88° without previous change.

(7) M. Hamberg and B. Samuelsson, *J. Biol. Chem.*, **241**, 257 (1965).

(8) P. W. Ramwell, J. E. Shaw, G. B. Clarke, M. F. Grostic, D. G. Kaiser, and J. E. Pike, "Progress in the Chemistry of Fats and other Lipids," R. Holman, Ed., Pergamon Press, Oxford, in press.